reports
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrati...
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following successful bridging study Topline data anticipated in the second half of 2028, approximately one year earlier than previously expected; Entera commits to a 12-month extension study to run in parallel with potential NDA review ...
- Wedbush Research
SHOP SHOPIFY INC.
WDC WESTERN DIGITAL CORPORATION
TRIP TRIPADVISOR INC.
STAA STAAR SURGICAL CO.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CRM SALESFORCE.COM INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
BBY BEST BUY CO. INC.
AXTI AXT INC.
2303 UNITED MICROELECTRONICS CORP.
CVNA CARVANA CO. CLASS A
ANAB ANAPTYSBIO INC.
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
SRRK SCHOLAR ROCK HOLDING CORPORATION
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
PASG INC.
BEAM PASSAGE BIO
DASH BEAM THERAPEUTICS
ABNB DOORDASH
PLTR AIRBNB INC. CLASS A
IMNM PALANTIR TECHNOLOGIES
SANA IMMUNOME
XMTR SANA BIOTECHNOLOGY
STX XOMETRY
TTD INC.
GFS SEAGATE TECHNOLOGY HLDGS PLC
MLTX THE TRADE DESK
PRME INC.
APGE GLOBALFOUNDRIES INC
CART MOONLAKE IMMUNOTHERAPEUTICS
IMA PRIME MEDICINE INC
VOYG APOGEE THERAPEUTICS INC
MAPLEBEAR INC.
IMAGENEBIO INC.
VOYAGER TECHNOLOGIES INC
- Chase Tohanczyn
- Matthew Weiss
- Scott Devitt
4Q25 Postmortem: Evaluating AI Risk in the Current Landscape
In this report, we establish an initial framework to assess exposure to AI-enabled risk across our coverage group. Specifically, we evaluate the risk of replacement, disintermediation, or both. Our framework measures structural defensibility and business model differentiation against the difficulty
SHOP SHOPIFY INC.
TRIP TRIPADVISOR INC.
MELI MERCADOLIBRE INC.
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CVNA CARVANA CO. CLASS A
SE SEA ADS
AMZN AMAZON.COM INC.
BKNG BOOKING HOLDINGS INC.
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
XMTR XOMETRY
TTD INC.
CART THE TRADE DESK
INC.
MAPLEBEAR INC.
Sparklight Launches Mobile Service with Limited-Time Offer of One Free...
Sparklight Launches Mobile Service with Limited-Time Offer of One Free Unlimited Line for 12 Months No-contract prepaid plans start at $15 per month, with one unlimited line free for 12 months for eligible internet customers PHOENIX, March 03, 2026 (GLOBE NEWSWIRE) -- As reliable mobile connectivity becomes increasingly essential for education, work, healthcare access and everyday life, , a leading broadband communications provider serving more than 1 million customers across 24 states, has introduced , expanding affordable wireless options for customers and reinforcing the company’s co...
Entera Bio to Participate in the Leerink Partners 2026 Global Healthca...
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference TEL AVIV, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the Leerink Partners Global Healthcare Conference 2026, details as below. Leerink Partners Global Healthcare Conference 2026 (Fireside Chat and 1x1 Meetings) Date and Time: March 11, 2026 at 10:40 a.m. E...
- Wedbush Research
WDC WESTERN DIGITAL CORPORATION
STAA STAAR SURGICAL CO.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EBAY EBAY INC.
CNK CINEMARK HOLDINGS INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
CVNA CARVANA CO. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
BKNG BOOKING HOLDINGS INC.
SMCI SUPER MICRO COMPUTER
DASH INC.
STX DOORDASH
GFS SEAGATE TECHNOLOGY HLDGS PLC
GLOBALFOUNDRIES INC
- Chase Tohanczyn
- Matthew Weiss
- Scott Devitt
600K Unit Margin Tune-Up; Outperform, $425 PT
Carvana reported strong revenue and unit growth, while GPU and adj. EBITDA were below expectations for 4Q. The company reported 4Q revenue of $5.6B (+58.0% Y/Y), ~7% ahead of St. expectations. While adj. EBITDA in the quarter was the highest quarterly amount the company has reported to date, totali
Carvana Co: 1 director
A director at Carvana Co sold 1,047 shares at 398.540USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
Entera Bio Announces Open Market Purchases of Company Stock by Board M...
Entera Bio Announces Open Market Purchases of Company Stock by Board Members TEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that several members of its Board of Directors, including the Company’s Chairman, have made open market purchases of the Company’s ordinary shares. These transactions follow an earlier open market purchase by Entera Bio’s Chief Executive Officer, Miranda Toledano, in December 2025. The purchases were made by Geno J. ...
Sparklight® Introduces the Next Evolution of Intelligent Wi-Fi with ee...
Sparklight® Introduces the Next Evolution of Intelligent Wi-Fi with eero Wi-Fi 7, Delivering Faster Speeds, Greater Capacity and Smarter Coverage PHOENIX, Feb. 11, 2026 (GLOBE NEWSWIRE) -- , a leading broadband communications provider, today announced the next evolution of its intelligent Wi-Fi experience with the introduction of eero Wi-Fi 7, bringing customers faster speeds, lower latency and greater capacity to support the growing number of smart devices in today’s connected homes. As households rely on Wi-Fi for nearly every aspect of daily life, from streaming and gaming to remote w...
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairma...
Entera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key Milestones New Chairman Joins Entera’s Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026 TEL AVIV, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that its Board of Directors has appointed Geno J. Germano as Chai...
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Clas...
OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism This is the third program that successfully combines Entera’s oral peptide N-Tab® platform with OPKO’s advanced protein chemistry capabilities The companies have accelerated this program and aim to file an investigational new drug (IND) application in late 2026 Injectable and oral oxyntomodulin (dual GLP-1/glucagon analog) for metabolic and fibrotic disorders advancing with initial Phase 1 data from injectable oxyntomodulin (OXM) expected in late 2026; o...
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipelin...
Entera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline Outlook Final EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026 Oral Hypoparathyroidism Tablet Program to Accelerate with Lead Long-Acting PTH Variants Strategic Partnership Discussions Advancing Across Pipeline JERUSALEM, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral...
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualificat...
Entera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA’s Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis Innovation FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613 Underscores Entera's mission to democratize anabolic treatment for osteoporosis patients and caregivers globally JERUSALEM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development ...
Moody's Ratings downgrades Cable One's ratings; outlook is stable
Moody's Ratings (Moody's) downgraded Cable One, Inc.'s (Cable One or the Company) Corporate Family Rating (CFR) to B1 from Ba3 and Probability of Default Rating (PDR) to B1-PD from Ba3-PD. We also downgraded all instrument ratings by one notch, including the Company's senior secured credit facilitie...
Entera Bio Announces New Data Supporting Further Development of a Prop...
Entera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program) Novel PTH analog achieves sustained calcium elevation for >3 days from single oral tablet, supporting development path toward once-daily alternative to daily injections JERUSALEM, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides and proteins replacement therapies, today announced new validating in vivo pharmacokinetic and phar...
- Wedbush Research
SHOP SHOPIFY INC.
KMX CARMAX INC.
TRIP TRIPADVISOR INC.
MELI MERCADOLIBRE INC.
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CVNA CARVANA CO. CLASS A
SE SEA ADS
AMZN AMAZON.COM INC.
BKNG BOOKING HOLDINGS INC.
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
XMTR XOMETRY
RIVN INC.
CART RIVIAN AUTOMOTIVE INC
CAMP MAPLEBEAR INC.
STUB CAMP4 THERAPEUTICS CORPORATION
KLAR STUBHUB HOLDINGS INC.
KLARNA GROUP PLC
- Chase Tohanczyn
- Daniel Ives
- Matthew Weiss
- Scott Devitt
SHOP SHOPIFY INC.
KMX CARMAX INC.
TRIP TRIPADVISOR INC.
MELI MERCADOLIBRE INC.
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CVNA CARVANA CO. CLASS A
SE SEA ADS
AMZN AMAZON.COM INC.
BKNG BOOKING HOLDINGS INC.
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
DASH DOORDASH
ABNB AIRBNB INC. CLASS A
XMTR XOMETRY
CART INC.
STUB MAPLEBEAR INC.
KLAR STUBHUB HOLDINGS INC.
KLARNA GROUP PLC
- Chase Tohanczyn
- Matthew Weiss
- Scott Devitt
Tough Road Ahead; Neutral, $36 PT
Figure 1. 3QFY26 Results vs. EstimatesSource: Company reports, Wedbush estimates, FactSet consensusCarMax reported results mostly in-line with lowered expectations for 3Q. In the quarter, the company reported revenue of $5.8B (-6.9% Y/Y), ~3% ahead of St. expectations of $5.6B (-9.9% Y/Y). 3Q retai
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.